Spark2Flame, Inc. (S2F) is developing Autism Spectrum Disorder (ASD) diagnostics and therapeutics. The company has licensed intellectual property from the Diamond laboratory at The Feinstein Institute for Medical Research, who has recently began cloning individual brain-reactive monoclonal antibodies from mothers of children with ASD. S2F has demonstrated that, when injected intravenously into pregnant mice, such monoclonal antibodies lead to abnormal brain development and ASD-related behavioral abnormalities in male but not female offspring. The goal is to use these brain-reactive monoclonal antibodies to advance a commercial ASD diagnostic (and ultimate therapeutic modality) that will identify mothers whose unborn child is at risk for this devastating disorder.
